Clinical trials: Umbilical Cord
Brain Injury, Cerebral Palsy
Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders
This open label trial is conducted to investigate the efficacy and safety of the combination therapy of allogeneic umbilical cord blood (UCB) and granulocyte-colony stimulating factor (G-CSF) for patients with brain injury or…
- Conditions
- Brain Injury, Cerebral Palsy, Amyotrophic Lateral Sclerosis, Parkinson's Disease
- Trial name
- NCT02236065
- Testing
- Umbilical cord blood therapy, Filgrastim
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- MinYoung Kim, M.D.
Type 2 Diabetes, Mesenchymal Stem Cells
Mesenchymal Stem Cells to Treat Type 2 Diabetes
Umbilical cord mesenchymal stem cells indicate the therapeutic effects and safety on type 2 diabetes by characteristics of secretion and immune Immunomodulation.
- Trial name
- UC-MSCs (NCT02302599)
- Testing
- Umbilical cord mesenchymal stem cells, Controlled suspension liquid
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Chinese PLA General Hospital
Leukemia, Myelodysplastic Syndromes
Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions
RATIONALE: Umbilical cord blood transplantation may allow doctors to give higher doses of chemotherapy or radiation therapy and kill more cancer cells.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00003336
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Case Comprehensive Cancer Center
Spinal Cord Injuries
Intrathecal Transplantation of UC-MSC in Patients With Late Stage of Chronic Spinal Cord Injury
This study aim to evaluate the safety and efficacy of intrathecal transplantation of allogeneic umbilical cord derived mesenchymal stem cells (UC-MSC) for treatment of different phrases of spinal cord injury.
- Trial name
- NCT03505034
- Testing
- Umbilical Cord Mesenchymal Stem Cells
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Lumbar Disc Degeneration, Lumbar Disc Herniation
Human Umbilical Cord Mesenchymal Stem Cells For the Treatment of Lumbar Disc Degeneration Disease
This study aims to investigate the safety and efficiency of Human Umbilical Cord Mesenchymal Stem Cells (hUCMSC) for treating lumbar disc degeneration diseases.
- Trial name
- NCT04414592
- Testing
- human umbilical cord mesenchymal stem cells
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Chronic Radiation Induced Intestinal Injury, Chronic Radiation Enteritis
Study on Safety and Efficacy of UCB-MNCs for Chronic Radiation Enteritis
This study aims to evaluate the safety and efficacy of the umbilical cord blood mononuclear cells (UCB-MNCs) therapy for chronic radiation enteritis (CRE) by observing factors related to the therapeutic effect and adverse…
- Trial name
- NCT07175207
- Testing
- UCB-MNCs
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Zhejiang Cancer Hospital
Cerebral Palsy (CP)
Intrathecal Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells for Children With Cerebral Palsy
This is a single-center, open-label, single-arm Phase I pilot study designed to evaluate the feasibility and short-term safety of a single intrathecal administration of allogeneic umbilical cord tissue-derived mesenchymal stromal…
- Trial name
- NCT07763028
- Testing
- allogeneic umbilical cord tissue-derived mesenchymal stromal cells (UCT-MSCs)
- Where
- Indonesia
- Volunteers
- 7 people
- Sponsor
- Gadjah Mada University
Duchenne's Muscular Dystrophy
Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (DMD)
This research study is designed to evaluate the effects of human umbilical cord mesenchymal stem cells (UC-MSCs), on Duchenne's muscular dystrophy (DMD).
- Trial name
- NCT02235844
- Testing
- Umbilical Cord Mesenchymal Stem Cells
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Allergy and Asthma Consultants, Wichita, Kansas
Acute Ischemic Stroke
Umbilical Cord-derived Mesenchymal Stem Cell Infusion for Treating Acute Ischemic Stroke
The goal of this clinical trial is to learn if drug mesenchymal stem cells (umbilical cord) injection works to treat acute ischemic stroke in adults.
- Trial name
- UMERIS (NCT06518902)
- Testing
- mesenchymal stem cells (umbilical cord) injection
- Volunteers
- 18 people
- Sponsor
- National Engineering Center of Cell Products
Hypoplastic Left Heart Syndrome
Safety and Feasibility Study of Umbilical Cord Blood Cells for Infants With Hypoplastic Left Heart Syndrome
Further study details as provided by Duke University: Purpose: To evaluate the feasibility and safety of collecting and infusing autologous umbilical cord blood (UCB) in newborn infants with hypoplastic left heart syndrome…
- Trial name
- NCT01445041
- Testing
- Autologous Umbilical Cord Blood
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Michael Cotten
Acute Ischemic Stroke
Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects With Acute Ischemic Stroke
This is a phase one study investigating the safety and efficacy profile of allogeneic cord blood hematopoietic progenitor cells (HPC, Cord Blood), when administered by intravenous infusion and intrathecal injection, in subjects…
- Trial name
- NCT03735277
- Testing
- HPC, Cord Blood
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- BHI Therapeutic Sciences
ST Elevation Myocardial Infarction
Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients
This phase IIa study is to identify the efficacy and safety of IC(intracoronary) and IV(Intravenous) administrations of UMSC01 in patients with STEMI .
- Trial name
- NCT06147986
- Testing
- Allogeneic umbilical cord mesenchymal stem cells, Control group
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- Ever Supreme Bio Technology Co., Ltd.
Hypoplastic Left Heart Syndrome
Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome
Researchers want to better understand what happens to the heart when the stem cells are injected directly into the muscle of the right side of the heart during the Stage II palliative surgery for single ventricle patients with…
- Trial name
- NCT03779711
- Testing
- Autologous (self) mononuclear cells derived from umbilical cord blood, Stage II Surgical repair
- Where
- 8 sites in United States
- Volunteers
- 95 people
- Sponsor
- Timothy J Nelson, MD, PhD
Hereditary Ataxia
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia
The Hereditary Ataxias are a group of genetic disorders characterized by slowly progressive incoordination of gait and often associated with poor coordination of hands, speech, and eye movements.
- Trial name
- NCT01360164
- Testing
- human umbilical cord mesenchymal stem cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Beike Bio-Technology Co., Ltd.
Diabetic Nephropathy Type 2
Human Umbilical Cord Mesenchymal Stem Cell Infusion for Type 2 Diabetic Nephropathy
Diabetic nephropathy (DN) is a chronic kidney disease caused by diabetes. It is one of the most common and most serious microvascular complications of diabetes. Current treatment options for DN are limited.
- Trial name
- NCT07769671
- Testing
- Human umbilical cord mesenchymal stem cell injection
- Where
- China
- Volunteers
- 49 people
- Sponsor
- The First People's Hospital of Changzhou
Skin Wound, Scar, Hypertrophic
Umbilical Cord Stem Cells for Skin Grafts in Donor Site Wounds
The goal of this clinical trial is to evaluate the safety and effectiveness of human umbilical cord mesenchymal stem cell (hUCMSC) therapy in patients undergoing medium-thickness skin grafts for donor site wounds.
- Trial name
- NCT05984628
- Testing
- human umbilical cord mesenchymal stem cells, blank solvent
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University Union Hospital
Safety Issues, Effect of Drugs
Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Cerebral Palsy
To study the clinical efficacy and safety of autologous umbilical cord blood transfusion in the treatment of cerebral palsy.
- Trial name
- NCT03791372
- Testing
- 0.9% Sodium Chloride, Autologous Umbilical Cord Blood
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Guangdong Women and Children Hospital
Fetal Hypoxia, Fetal Monitoring
Evaluation of the Fetal Response to Intrapartum Digital Fetal Scalp Stimulation to Identify Intrapartum Fetal Hypoxia.
The main objective of this study is to evaluate whether digital fetal scalp stimulation improves fetal well-being in fetuses with suspicious or pathological cardiotocographic recordings, showing an improvement in…
- Trial name
- NCT07035028
- Testing
- Digital fetal scalp stimulation dFSS
- Where
- 2 sites in Spain
- Volunteers
- 182 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Other Surgical Procedures
Safety and Efficacy of Stem Cell Transplantation for Treatment of Liver Cirrhosis
Mainstream of current treatment of liver cirrhosis is liver transplantation, but there are high cost, risk and immune rejection and other issues.
- Trial name
- NCT01491165
- Testing
- stem cell transplantation through interventional procedures
- Where
- China
- Volunteers
- 75 people
- Sponsor
- General Hospital of Chinese Armed Police Forces
Inherited Metabolic Disorders (IMD)
MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
This study is designed to assess the safety and efficacy of using MGTA-456 in patients with Inherited Metabolic Disorders (IMD) undergoing stem cell transplantation.
- Trial name
- NCT03406962
- Testing
- MGTA-456
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Magenta Therapeutics, Inc.